Humacyte (HUMA) to Release Earnings on Friday

Humacyte (NASDAQ:HUMA - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect Humacyte to post earnings of ($0.19) per share and revenue of $0.46 million for the quarter.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to analysts' expectations of $0.64 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Performance

Shares of HUMA stock opened at $1.41 on Friday. The stock has a market capitalization of $218.72 million, a P/E ratio of -1.05 and a beta of 1.62. The company has a 50 day moving average price of $2.19 and a 200 day moving average price of $3.79. Humacyte has a fifty-two week low of $1.15 and a fifty-two week high of $9.97.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on HUMA shares. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. Finally, Benchmark reiterated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $13.71.

Insider Buying and Selling

In other Humacyte news, Director Kathleen Sebelius purchased 50,000 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the acquisition, the director now owns 91,207 shares of the company's stock, valued at approximately $120,393.24. The trade was a 121.34 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction on Thursday, April 10th. The stock was acquired at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. The trade was a 97.09 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 83,993 shares of company stock worth $118,224 in the last ninety days. Insiders own 11.20% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.